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Clostridium difficile (Peptoclostridium difficile) is a common health care-associated infection with a disproportionately high
incidence in elderly patients. Disease symptoms range frommild diarrhea to life-threatening pseudomembranous colitis.
Around 20% of patients may suffer recurrent disease, which often requires rehospitalization of patients. C. difficile was isolated
from stool samples from a patient with two recurrent C. difficile infections. PCR ribotyping, whole-genome sequencing, and
phenotypic assays were used to characterize these isolates. Genotypic and phenotypic screening of C. difficile isolates revealed
multiple PCR ribotypes present and the emergence of rifamycin resistance during the infection cycle. Understanding both the
clinical and bacterial factors that contribute to the course of recurrent infection could inform strategies to reduce recurrence.
(This study has been registered at ClinicalTrials.gov under registration no. NCT01670149.)
Clostridium difficile (Peptoclostridium difficile) is a commonhealth care-associated infection with a disproportionately
high incidence in elderly patients. Recurrent Clostridium difficile
infection (CDI) is known to occur in approximately 20% of pa-
tients following withdrawal of treatment antibiotics (1); however,
thismay rise to 65% if a patient has a history of CDI (2). Recurring
CDI not only causes distress to patients but is also a substantial
burden on the health care system due to the increased cost (3)
associated with possible prolonged stay or readmission of a pa-
tient to the hospital and the readministration of diagnostic tests
and antibiotics (4). Collaborations between clinicians and re-
searchers are contributing to knowledge of how both the host and
bacterium are affecting recurrent disease in order to reduce recur-
rence rates through personalized patient care regimens (5).
In this study, multiple stool samples from a patient enrolled in
a clinical trial were collected and C. difficile was isolated. The
strains isolated from these samples were then phenotypically and
genotypically characterized to deduce if changes in the C. difficile
strain genotype and phenotype could have contributed to recur-
rent infection.
Case. A male participant (01008), aged 85 years, had a history
of chronic kidney disease and was on multiple long-termmedica-
tions, including bumetanide, candesartan, digoxin, simvastatin,
doxazosin, ferrous fumarate, and prednisolone. Three months
prior to trial enrollment the participant received cefuroxime and
gentamicin for a urinary tract infection. One month prior to trial
enrollment he was admitted to the hospital, where he received
clindamycin (both orally and intravenously) for an infected leg
ulcer.
In June 2013, after being readmitted to the hospital, he was
diagnosed with CDI (Table 1, sample A), treated with metronida-
zole (MET), and discharged. He was diagnosed again with CDI in
July (Table 1, sample B) and was treated again with MET.
In July 2013, within 5 days of cessation of successful treatment
of CDI with MET (defined as cessation of diarrhea for 2 or more
days with no loose stools assessed), he was enrolled in a random-
ized double-blind placebo-controlled clinical research trial aimed
at using rifaximin for reducing relapse of Clostridium-associated
diarrhea (RAPID-ClinicalTrials registration no. NCT01670149).
A simplified study time line of stool sample collection is outlined
in Fig. 1.
The participant successfully provided one trial stool sample
(Table 1, sample C). However, within 10 days he suffered another
diarrheal episode (Table 1, sample D), which was initially toxin
negative as confirmed using the C. Diff Quik Chek complete kit
(Alere) and PCR using the BD MAX Cdiff kit (BD Molecular
Diagnostics). However, 6 days after sample D, he provided an-
other sample (Table 1, sample E) which was toxin positive and
therefore defined as relapse according to the RAPID trial protocol
(onset of3 loose bowel movements per day for at least 2 consec-
utive days combined with a positive toxin assay [with or without a
positiveC. difficile culture]). He was treated withMET and, over 8
to 10 weeks, provided two more trial samples (Table 1, samples F
and G). Participant notes revealed that during the period when he
providedmore RAPID samples, he was again diagnosed with CDI
(September) and treated with vancomycin (VAN).
The participant was again admitted to the hospital and treated
with tazocin and subsequently suffered another CDI (Table 1,
sample H) around his time of death in January 2014 due to mul-
tiple organ failure. As this was a randomized double-blind, place-
bo-controlled clinical research trial, it was not known if partici-
pant 01008 was on placebo or rifaximin therapy at the point at
which this research was undertaken.
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MATERIALS AND METHODS
A total of eight stool samples were collected from the participant (Table
1). These included diagnostic specimens from theQueensMedical Centre
(QMC) microbiology department, Nottingham, that were proven C. dif-
ficile toxin positive by using the C. Diff Quik Chek complete kit (Alere)
and PCR using the BD MAX Cdiff kit (BD Molecular Diagnostics). C.
difficile was cultured from 300 mg of stool using a previously pub-
lished protocol (6). One to 20 C. difficile colonies were isolated per
sample (Table 2).
C. difficile typing. After 48 h of growth on cefoxitin cycloserine egg
yolk (CCEY) (6) agar, up to 20 individual C. difficile colonies from each
stool specimen were inoculated into a single well of a 96-well plate con-
taining 200 l anaerobic brain heart infusion (Oxoid) plus 0.1% L-cys-
teine (Sigma) (BHIS) broth, leaving one well blank as a control. The plate
was sealed with a breathable sterile film and incubated for 24 h in an
anaerobic workstation (Don Whitley) (CO2:H2:N2 at 80:10:10, vol/vol/
vol). After 24 h the wells were checked for turbidity. Overnight cultures
were then diluted 10-foldwith sterile PCR-gradewater into a fresh 96-well
plate, sealed with film, and stored at 20°C until required. One drop of
100% glycerol was added to the BHIS cultures, and the plate was stored at
80°C until required. Every colony that was isolated from each stool
sample was subjected to in-house ribotyping with the diluted cultures as
mentioned above. PCR amplification of the 16S rRNA intergenic spacer
regionwas carried out according to amodifiedprotocol obtained from the
former C. difficile ribotyping laboratory in Cardiff (see the supplemental
material). PCR-ribotype profiles were analyzed with a QIAxcel capillary
electrophoresis machine (Qiagen) using the OL400 program with the QX
15-bp to 1-kb alignmentmarker and theQX 50-bp to 800-bp sizemarker.
Individual profiles were assessed, and then one isolate from each distinct
typing profile that had been obtained from each stool sample was recul-
tured onto BHIS-CC agar and stored as a glycerol stock.
These stock strains were sent for official ribotyping via the C. difficile
ribotyping network (CDRN) service in Leeds and used for downstream
characterization.
Phenotypic characterization.Growth, sporulation, and toxinA andB
enzyme-linked immunosorbent assays (ELISAs) were performed on all
isolates (see the supplemental material).
Antibiotic susceptibility. Isolated strains were tested for antibiotic
resistance to metronidazole (MET) and vancomycin (VAN), using the
Etestmethod (Oxoid), and rifampin (RIF) and rifaximin (RFX) resistance
by broth dilution (see the supplementalmaterial) using a 2-fold antibiotic
dilution range from 512 to 0.5 g/ml. C. difficile 630erm, 630 wild-type
(WT), and R20291 strains were used as controls. Guideline MIC break-
points for RIF and RFX were taken from reference 7, where isolates with
MICs of 32 g/ml were considered resistant. Intermediate resistance
was defined as a MIC of 0.003 to 32 g/ml (8).
Genotypic characterization. DNA was extracted from strains using
an extraction method with phenol-chloroform-isoamyl alcohol (25:24:1)
saturated with 10 mM Tris, pH 8.0, 1 mM EDTA (Sigma) (adapted from
reference 9; see also the supplemental material).
Whole-genome comparison. Genomic DNA was sent for Illumina
sequencing using MisSeq 250-PE technology (DeepSeq; University of
Nottingham). DNA from one of the isolates from sample A (earliest
RT002 isolate) and sample E (earliest RT014 isolate identified), desig-
nated E2, were also sent for Pacific Bioscience (PacBio) sequencing
(McGill University and Genome Québec Innovation Centre). Paired-end
reads from the MiSeq runs were mapped to PacBio contigs using CLC
Genomics Workbench, version 8.0.2 (Qiagen).
Concordance of PacBio and Illumina sequencing. To demonstrate
the concordance of two different sequencing methods (especially over
homopolymer regions), Illumina paired-end sequencing reads from iso-
late A and E2 were mapped back to the PacBio reference contigs. Basic
variant detection (CLC Genomics Workbench, version 8.0.2 [Qiagen])
was used to call single-nucleotide variations (SNVs), insertions, and de-
letions. All default parameters were kept the same, apart from the mini-
mum frequency setting in the coverage and count filter process. Themin-
imum frequency setting was changed to 50% to try to capture as many
high-quality changes as possible.
RESULTS
Ribotype of Clostridium difficile isolates obtained from stool.
During the course of infection, two distinct C. difficile PCR ri-
botypes were isolated (Table 2). The predominant PCR ribotype
occurring during the infectionwas RT002. Coinfection of the par-
ticipant with a second PCR ribotype (RT014)was detected in stool
sample E. This sample was a diagnostic sample obtained after the
participant had suffered the first relapse (Table 2). However, it
cannot be deduced whether this PCR ribotype was present in ear-
lier samples (i.e., C or D) due to the small number of colonies
obtained from the stools of these samples. Therefore, the RT014
isolate may have been present at low frequency in these samples.
Isolate growth, sporulation, and toxinquantification.All iso-
lates showed similar growth profiles in both BHIS and TY (data
not shown) except isolate G. This isolate had a shorter stationary
phase when grown in BHIS and reduced growth in TY broth.
However, this did not affect sporulation and toxin titer, as there
were no significant differences in these phenotypes between any of
the isolates (data not shown).
Pacific Bioscience and Illumina MiSeq sequencing of RT002
and RT014 isolates. The PacBio sequencing was able to assemble
the genome of isolate A into four contigs (Table 3) and isolate E2
into one contig of 4,330,205 bp. Contigs were identified by means
of BLAST searches using the dc-megablast option against the nu-
cleotide database. BLAST analysis of the one contig from isolate
E2 suggests that it shares sequence similarity with the Peptoclos-
TABLE 1 Description and date of sample collection for participant
01008 in the RAPID trial
Sample
ID Specimen
Sample collection
date (day/mo/yr)
A 1st diagnostic samplea 21/6/2013
B 2nd diagnostic samplea 1/7/2013
C Week 0 (visit 1) RAPID sample 9/7/2013
D Relapse sample 1 19/7/2013
E Diagnostic sample post relapse sample 1a 27/7/2013
F Week 4 (visit 3) RAPID sample 7/8/2013
G Week 12 (visit 5) RAPID sample 2/10/2013
H Relapse sample after week 12 (visit 5)
RAPID sample
4/1/2014
a Samples obtained from the Queens Medical Centre Microbiology Department.
FIG 1 Simplified study timeline indicating the collection of stool samples for
the participants involved in the RAPID trial.
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tridium difficile genome assembly CD630DERM, chromosome 1
(LN681537.1).
The individual contigs were annotated using RAST (10) and
used as reference strains for Illumina read mapping of all isolates.
Over 97%of reads from sevenRT002 isolates (A, B, C, D, E1, F,
and G) and 97% of reads from two RT014 isolates (E2 and H)
mapped to the reference PacBio contigs for the corresponding
PCR ribotype.
Concordance of PacBio and Illumina sequencing.Nine SNVs
were identified in all of the RT002 genomes, and 12 SNVs were
detected when Illumina MiSeq reads were mapped back to their
respective PacBio contigs. All SNVs of the RT002 isolates occurred
in the first contig, which represented themainC. difficile chromo-
some. All of the SNVs from both RT002 and RT014 isolates oc-
curred in homopolymer regions of4 nucleotides in length. PCR
amplification and Sanger sequencing of all the regions in isolate A
and E2 that contained the SNVs confirmed that they were true
SNVs. Accordingly, the reference sequences A and E2 were cor-
rected and the sequence reads from the subsequent isolates (B to
G) were remapped.
SNV detection in RT002 isolates. Basic variant detection was
performed on the reads to assess whether the sequential isolates
contained additional changes from the original (A) isolate (Table
4). Isolate B did not contain any additional SNVs. Isolate C con-
tained one additional SNV. The AG nucleotide change did not
result in an amino acid change. Isolates D and E1 both contained
the same four additional SNVs compared to isolate A, two of
which were nonsynonymous and found in oppF and rpoB (Table
4). The former encodes an oligotransport-ATP binding domain,
while the latter encodes a DNA-directed RNA polymerase beta
subunit. These two isolates did not contain the SNV found in
isolate C. Isolate F contained five SNVs compared to the sequence
of isolate A; however, these were not the same as any SNVs in
previous isolates. One of the SNVs in isolate F was found in the
same gene (rpoB) but not at the same position as in isolates D and
E1. Variant detection in isolate G produced 70 SNVs. Closer in-
spection of these SNVs revealed that 64 were detected at low fre-
quency in poorly mapped regions and probably were not real.
Thus, this isolate had six SNV differences compared to isolates A
and B (Table 4). Five SNVs were in the same regions as isolate F,
with two of the SNVs, in a hypothetical protein and rpoB, being in
the exact same location as in isolate F (Table 4).
SNV detection in RT014 isolates. Six additional SNVs were
found in isolateH compared to isolate E2. Five of these SNVswere
in a gene annotated as fliK, which is not actually part of the flagel-
lar operon.Only two of these five SNVswere nonsynonymous and
occurred at a frequency of 52% and with an average quality of
22. Closer inspection of this region revealed that the sequence
quality was poor most likely due to its being repetitive, suggesting
that these SNVs were not real. Thus, only one additional TC
SNV was identified. The SNV was in an intergenic region of the
genome of isolate H, at position bp 2562170, upstream of a gene
encoding a small hypothetical protein that shows similarity to a
putative membrane protein.
Isolate antibiotic resistance. No isolate showed resistance to
MET (breakpoint considered resistant, 2 g/ml) or VAN
(breakpoint considered resistant, 4 g/ml) (data not shown).
Early RT002 isolates A, B, andC showed complete susceptibility to
RIF andRFX (see Fig. S1a and b and S2a and b in the supplemental
material). However, RT002 isolates D (from the relapse sample)
and E1 (postrelapse sample) showed high resistance (256 g/
ml) to RIF and RFX (128 g/ml), while RT002 isolates F and G
showed intermediate resistance to both (RIF, 4 g/ml;
RFX, 16 g/ml). The RT014 isolates (E2 and H) and control
strains were fully susceptible to RIF and RFX (0.5 g/ml) (see
Fig. S1a and 1b and S2a and b).
Frequency of rpoB SNVs in all culturedA-to-GRT002 isolate
samples. To discern whether there were two distinct populations
of RIF- and RFX-resistant RT002 isolates, the region in rpoB that
contained the SNVs identified in Table 4 was amplified from every
isolate with a PCR ribotype banding pattern confirmed with
QIAxcel (Table 1). The PCR-amplified DNA fragment was sent
for Sanger sequencing, and the sequences were checked for the
TABLE 2 PCR ribotype of isolates obtained from participant 01008 stool samples
Sample ID Specimen
Sample collection
date
Number of colonies
obtained/typeda PCR-ribotype of isolateb
A 1st diagnostic sample 21/6/13 20/8 002
B 2nd diagnostic sample 1/7/13 20/20 002
C Week 0 (visit 1) RAPID sample 9/7/13 1/1 002
D Relapse sample 1 19/7/13 8/5 002
E Diagnostic sample post relapse sample 1 27/7/13 20/20 E1-002 (7), E2-014 (13)
F Week 4 (visit 3) RAPID sample 7/8/13 15/14 002
G Week 12 (visit 5) RAPID sample 2/10/13 20/20 002
H Relapse sample after week 12 (visit 5) RAPID sample 4/1/14 20/20 014
a In-house capillary electrophoresis typing using a QIAxcel.
b Numbers in parentheses represent the frequency of that PCR-ribotype pattern.
TABLE 3 PacBio contig assembly information from RT002 isolate A
Contig PacBio BLAST identification Contig size (bp)
1 FN668944.1, Clostridium difficile BI9 chromosome 4,207,942
2 LN681537.1, Clostridium phage phiCD211, complete genome 140,450
3 FN668942.1, Clostridium difficile BI1 plasmid pCDBI1, complete sequence 65,380
4 GU949551.1, Clostridium phage phiCD6356, complete genome 52,160
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above-described SNVs. The frequency of these SNVs in each iso-
late is detailed in Table 5.
DISCUSSION
The recurrent infection suffered by participant 01008 is onewhich
is endured by up to 20% of patients suffering from CDI (1). Over
a 180-day period, this particular individual relapsed twice with
CDI and presented with coinfection by two different PCR ri-
botypes. At one point during the infection, the participant also
either acquired an RT002 isolate, which was resistant to rifamy-
cins (reinfection), or the original isolate developed rifamycin re-
sistance due to microevolution (relapse). The combination of
these factors could have contributed to the persistence of this par-
ticipant’s infection.
The nature of the RAPID trial is to recruit participants at the
end of their standard CDI therapy, when the patient has been
assessed as being resolved of CDI. The participant is then started
on a regimen of either RFX or placebo for 4 weeks, during which
stool samples are collected. The participant is then monitored for
another 8 weeks, during which more stool is collected. As this was
a randomized double-blind placebo-controlled clinical research
trial, at the point at which this research was undertaken, it was not
known if participant 01008 was on placebo or rifaximin therapy.
What is clear from this data is that even though this participant
was deemed to have resolved symptoms of CDI prior to trial en-
rollment, there was still a low level of C. difficile in the stool (as
indicated by the isolation ofC. difficile from sample C), and in this
participant it may have contributed to the recurrence of disease.
There is further genetic evidence to suggest that the RT002 isolate
found in the preenrollment diagnostic specimens (A and B) had
persisted, at least until the next sample specimen (C). According
to others (11–13), genetically identical strains differ by2 SNVs,
and there was only one SNV difference between isolate A/B and C.
At some point during the time between sample C and sample D,
participant 01008 either acquired a genetically distinct RT002 iso-
late (reinfection) with resistance to RIF and RFX or the original
TABLE 4 Additional SNVs in genome of sequential RT002 isolates
Strain
Reference
position Type Reference Allele Count Coverage Frequency
Avg
quality
Change
Coding region Amino acid
C 319864 SNV A G 194 201 96.52 33.44 Choline binding protein A:c.6498AG
D 147783 SNV A T 189 192 98.44 36.37 Aminobenzoyl-glutamate transport
protein:c.210TA
D 556338 Deletion A 177 177 100.00 31.07 Oligopeptide transport ATP-binding protein OppF
(TC 3.A.1.5.1):c.479delA
p.Gln160fs
D 2974068 SNV G A 210 233 90.13 36.21
D 3762293 SNV C A 189 191 98.95 36.61 DNA-directed RNA polymerase beta subunit
(EC 2.7.7.6):c.1465CA
p.Gln489Lys
E1 147783 SNV A T 195 198 98.48 34.89 Aminobenzoyl-glutamate transport
protein:c.210TA
E1 556338 Deletion A 146 149 97.99 32.74 Oligopeptide transport ATP-binding protein OppF
(TC 3.A.1.5.1):c.479delA
p.Gln160fs
E1 2974068 SNV G A 151 211 71.56 36.64
E1 3762293 SNV C A 161 161 100.00 36.15 DNA-directed RNA polymerase beta subunit
(EC 2.7.7.6):c.1465CA
p.Gln489Lys
F 1181867 SNV G T 172 174 98.85 33.01 FIG00512976: hypothetical protein:c.722CA p.Thr241Asn
F 1861424 SNV A G 158 168 94.05 31.75
F 1861431 SNV G A 171 172 99.42 35.88
F 2676955 SNV A C 231 233 99.14 35.90
F 3762308 SNV A T 204 207 98.55 34.08 DNA-directed RNA polymerase beta subunit
(EC 2.7.7.6):c.1475AT
p.Asp492Val
G 1181870 SNV G T 33 33 100 37.12 FIG00512976: hypothetical protein:c.722CA p.Thr241Asn
G 1861429 SNV A G 21 21 100 32.95
G 1861436 SNV G A 22 22 100 37.64
G 2676961 SNV A C 12 12 100 38.67
G 3762308 SNV A T 143 174 82.18 36.96 DNA-directed RNA polymerase beta subunit
(EC 2.7.7.6):c.1475AT
p.Asp492Val
G 3040149 SNV C A 21 33 63.64 38.24 FIG00534171: hypothetical protein:c.13GT p.Glu5*
TABLE 5 Frequency of all cultured RT002 isolates with and without rpoB SNVs
Sample ID Specimen No. of colonies typed SNV present*
A 1st diagnostic sample 8
B 2nd diagnostic sample 20
C Week 0 (visit 1) RAPID sample 1
D Relapse sample 1 5 	, (4), [CA],(1)
E Diagnostic sample post relapse sample 1 7 	
F Week 4 (visit 3) RAPID sample 14 	, [AT (13)],	, [CA, (1)]
G Week 12 (visit 5) RAPID sample 20 	, (10), [AT],(10)
a Absence () or presence (	) of SNV is indicated. Numbers in parentheses are the frequency of the isolates with or without SNV. Brackets identify which SNV was present.
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RT002 isolate evolved to become RIF and RFX resistant (256
g/ml and128 g/ml, respectively). Prior to sample D, isolates
from samples A, B, and C did not contain SNVs in the rpoB gene
(Table 5), supporting the notion that participant 01008 was prob-
ably colonizedwith one population of nonresistant RT002 isolates
at the time of the infection. In other studies (11, 12), genetically
distinct isolates are differentiated by 10 SNVs. Here, isolate D
differed by only four SNVs compared to isolates A, B, and C, and
within the population of isolates from sample D (Table 5) one
isolate did not contain the SNV in the rpoB gene. Thus, it is not
possible to deduce whether this was a newly acquired isolate or
whether the initial strain had mutated. It is possible that the
RT002 isolate in this infection was under high antibiotic selection
pressure and, thus, may have mutated more rapidly than others
have calculated for strains not under intense selection pressure
(14).
Whole-genome sequencing of isolates A to H revealed that the
probable cause of RIF and RFX resistance in isolate D was a CA
SNV at bp 1465 in the rpoB gene, encoding a DNA-directed RNA
polymerase beta subunit (Table 4). Mutations in rpoB have been
identified in C. difficile (7, 8) and also occur in multidrug-resis-
tant strains of Mycobacterium tuberculosis (15) within a small
23-amino-acid region fromposition 511 to 533 (16). This suggests
a common mechanism by which resistance to this antibiotic oc-
curs in multiple bacterial species.
The SNV in isolate D resulted in a glutamine-to-lysine amino
acid change at position 489 of the peptide. It is known that the
glutamine residue at the corresponding position of RpoB in Ther-
mus aquaticus directly binds to rifampin (7, 17). Thus, it is likely
that this SNV is directly responsible for resistance to RIF and RFX
in this isolate, and this may have played a role in the first relapse
suffered by this participant. A subsequent stool specimen from
participant 01008 revealed the presence of an RT002 isolate (E1)
genetically identical to isolate D, which also shared the same SNV
change in rpoB and was also RIF and RFX resistant (256 g/ml
and 128 g/ml, respectively). The sample also contained an-
other ribotype (RT014; isolate E2). Isolate E2 was fully sensitive to
RIF and RFX. If participant 01008 was on RFX therapy, then it is
unlikely that isolate E2 contributed to the relapse, as clearly the
vegetative form of the isolate is susceptible to the rifamycins and
would have been killed. However, whether or not the isolate was
present just prior to relapse is not discernible, as it was only pos-
sible to isolate one colony from the prerelapse sample C. The
RT014 isolate (E2) may have been present in the host at low levels
in the spore form, evading the effects of possible antibiotic therapy
and persisting until a timewhen it could germinate and grow. This
hypothesis is supported by the emergence of the RT014 (H) isolate
in the final stool sample which was genetically indistinct from
isolate E2.
Isolates D and E1 also shared an SNV in the oligotransport-
ATP binding domain of oppF (Table 4), which belongs to an
operon of oligopeptide permease (opp) genes that are involved in
regulating sporulation (among other processes) in some species of
Bacillus and Clostridium (18, 19). In vitro sporulation studies on
all isolates revealed no significant difference (data not shown) in
the rate of sporulation between isolate D and E1 and all other
isolates. However, these data may not be representative of in vivo
sporulation characteristics; therefore, it cannot be conclusively
proven that this SNV had no effect. The opp operon is involved in
other processes in other organisms, for example, competence in
Bacillus and Streptococcus species, plasmid transfer in Enterococcus
faecalis, and the expression of virulence factors in Bacillus thurin-
giensis (18, 20). Therefore, SNVs in this region may have a yet-
undiscovered role in C. difficile virulence and could present a fur-
ther avenue of research.
The next specimen provided by the patient revealed the pres-
ence of an RT002 isolate (F) with five additional SNVs compared
to isolates A, B, andC. Four of the SNVswere completely different
from the previous isolate (E1) and isolate D. However, one SNV
was again located in rpoB, at a different position (bp 1475), result-
ing in an AT change that caused an amino acid change from
aspartic acid to valine at position 492 of the peptide. The alteration
of this aspartic acid residue to other amino acids, including valine,
has been shown to result in RIF resistance in Staphylococcus aureus
(7, 21). Unlike the RpoB amino acid changes in isolates D and E1,
theRpoB amino acid change in isolate F apparently conferred only
intermediate resistance to RIF (4 g/ml) and RFX (g/ml).
The SNV at this positionwas also shared by the final RT002 isolate
found in sample G, which showed the same level of resistance to
RIF and RFX. Whether or not this level of resistance would be
sufficient to contribute to the persistence of the organism in the
colon is unclear, but there is clearly selective pressure for this
mutation occurring either in the host or within the C. difficile
population found at the QMC in Nottingham.
The presence of an SNV in the same gene (rpoB) but at differ-
ent positions within the RT002 isolates supports the notion that
two distinct subpopulations of RIF- andRFX-resistant RT002 iso-
lates could have coexisted in this participant. Further sequencing
of this region in sample E RT002 isolates revealed that they all
shared the same CA SNV. However, one of the 15 sample F
isolates cultured (Table 5) contained the CASNV found in sam-
ple E isolates and not the AT SNV found in the remaining F
isolates, indicating that two subpopulations of RT002 isolates
could have coexisted at this point. Among the sample G isolates,
there were equal populations of isolates with and without any
SNVs in rpoB. This either indicates the persistence of the initial
susceptible isolate in the gut or that at the time sampleGwas taken
the population was in a transient state of mutation.
It is relevant to note that other studies have documented cases
of C. difficile rifamycin resistance after chaser therapies using ri-
faximin (8, 22, 23). One of these studies has linked this resistance
to mutations in RpoB (8) that have been identified by others (7).
The study by Curry et al. (8) indicates that in their study popula-
tion, more than one-third of isolates were resistant to rifaximin,
and this is something which could be looked at in a wider popu-
lation of participants in the RAPID trial, as it may prompt clini-
cians to alter dosing regimens if the therapy was approved for use
in patients suffering recurrence.
Conclusions. This case study has presented insight into the
course of recurrent infection caused by C. difficile. In this case it
was difficult to ascertain whether, in this particular individual, the
C. difficile strain was evolving. However, it did reveal the possible
presence of multiple isolates with SNVs causing distinct fitness
advantages. The fact that this participant was enrolled in a trial to
investigate the use of RFX to prevent recurrence suggests that we
should be monitoring mutations in the rpoB gene more closely in
the isolates from trial patients, as a side effect of this therapy could
be the increased selection for RFX-resistantC. difficile strains. This
is of importance to clinicians, as it may directly impact the antibi-
otic regimen they use to treat their patient.
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The advent of high-throughput technologies will allow for
more in-depth screening of samples to elucidate the true genetic
fingerprint of the isolates found during infection. When coupled
with in-depth microbiome analysis of the host, this may allow
researchers tomore fully comprehend the overall picture of recur-
rent infection and, in turn, translate this information to clinicians
in order tomanage at-risk patientsmore effectively and reduce the
morbidity and economic burden of C. difficile within the health
care system.
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